The role EPO plays in iron-deficiency-related thrombocytosis has garnered much interest, as administration of human recombinant EPO (rh-EPO) results in thrombocytosis of varying degree and duration in healthy controls [34] as well as patients with chronic kidney disease [35]. This evidence concerns the gene EPO and chronic kidney disease.